Presbia (LENS)

Executive Summary

Presbia is a US-based ophthalmic device company developing the Flexivue Microlens, a corneal inlay designed to restore near and intermediate vision in presbyopic patients. The device offers a minimally invasive alternative to reading glasses or multifocal contact lenses, addressing a large and growing market as the global population ages. Presbia's technology aims to provide a durable, reversible solution with a simple implantation procedure. The company has faced challenges in commercial adoption and regulatory hurdles but continues to refine its product and clinical evidence. With an established patent portfolio and a focused strategy on refractive surgery centers, Presbia is positioned to capture share in the presbyopia correction market. The company's success hinges on gaining regulatory approvals (e.g., FDA clearance) and building surgeon confidence through long-term safety and efficacy data.

Upcoming Catalysts (preview)

• Q4 2026FDA approval or clearance for Flexivue Microlens45% success
• Q2 2026Presentation of pivotal clinical trial results60% success
• Q3 2026Strategic partnership or licensing deal for US commercialization35% success